-Reuters
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)
15-12G - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
10-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. (("Maxpro", NASDAQ:JMAC). Apollomics' Class A ordinary shares and public warrants are expected to commence trading today, March 30, 2023, on the Nasdaq Capital Market (Nasdaq) under the symbols "APLM" and "APLMW," respectively. The Business Combination, which was approved by Maxpro's shareholders on March 20, 2023,
Taipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company") announced today that its sponsor, MP One Investment LLC (the "Sponsor") and Apollomics Inc. ("Apollomics"), deposited additional payments in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the "Extension Payment") into the Company's trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from January 13, 2023 to April 13, 2023 (the "Extension"). The Extension is the second of two three-month extensions permitted under the Company
TAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company"), announced today that its sponsor, MP One Investment LLC (the "Sponsor"), has requested that the Company extend the date by which the Company has to consummate a business combination from January 13, 2023 to April 13, 2023 (the "Extension"). The Extension is the second of two three-month extensions permitted under the Company's governing documents. In connection with the Extension, the Sponsor and Apollomics Inc. ("Apollomics") have notified the Company that they intend to bear the cost of the Extension in the aggregate amount of $1,035,000 (representing $0.10 pe
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)
SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)